Proto Script Pharmaceutical (Proto Script Pharmaceutical) Operating Income : $-0.97 Mil (TTM As of Sep. 2017)

View and export this data going back to 2011. Start your Free Trial

What is Proto Script Pharmaceutical Operating Income?

Proto Script Pharmaceutical's Operating Income for the three months ended in Sep. 2017 was $-0.09 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2017 was $-0.97 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Proto Script Pharmaceutical's Operating Income for the three months ended in Sep. 2017 was $-0.09 Mil. Proto Script Pharmaceutical's Revenue for the three months ended in Sep. 2017 was $0.25 Mil. Therefore, Proto Script Pharmaceutical's Operating Margin % for the quarter that ended in Sep. 2017 was -33.73%.

Proto Script Pharmaceutical's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Proto Script Pharmaceutical's annualized ROC % for the quarter that ended in Sep. 2017 was -29.22%. Proto Script Pharmaceutical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2017 was -1,619.51%.

Proto Script Pharmaceutical Operating Income Historical Data

The historical data trend for Proto Script Pharmaceutical's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proto Script Pharmaceutical Operating Income Chart

Proto Script Pharmaceutical Annual Data

Trend

May12

May13

May14

May15

May16

Operating Income

-0.03

-0.05

-0.03

Proto Script Pharmaceutical Quarterly Data
	Nov12	Feb13	May13	Aug13	Nov13	Feb14	May14	Aug14	Nov14	Feb15	May15	Aug15	Nov15	Feb16	May16	Sep16	Dec16	Mar17	Jun17	Sep17
Operating Income	Get a 7-Day Free Trial															-	-0.38	-0.26	-0.24	-0.09

Proto Script Pharmaceutical Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.97 Mil.

Proto Script Pharmaceutical (OTCPK:PSCR) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Proto Script Pharmaceutical's annualized ROC % for the quarter that ended in Sep. 2017 is calculated as:

	ROC % (Q: Sep. 2017 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2017 )	+	Invested Capital (Q: Sep. 2017 ))	/ count )
=	-0.34 * ( 1 - 0% )	/	( (1.037	+	1.29)	/ 2 )
=	-0.34	/	1.1635
=	-29.22 %

where

	Invested Capital		(Q: Jun. 2017 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.166	-	0.337	-	( 0	-	max(0, 1.324	-	0.116	+	0	))
=	1.037

	Invested Capital		(Q: Sep. 2017 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.235	-	0.434	-	( 0	-	max(0, 1.676	-	0.187	+	0	))
=	1.29

Note: The Operating Income data used here is four times the quarterly (Sep. 2017) data.

2. Joel Greenblatt's definition of Return on Capital:

Proto Script Pharmaceutical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2017 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2017 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2017		Q: Sep. 2017
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.664	/	( ( (0.042 + max(-0.97, 0))	+	(0.04 + max(-1.116, 0)) )	/	2 )
=	-0.664	/	( ( 0.042	+	0.04 )	/	2 )
=	-0.664	/	0.041
=	-1,619.51 %

where Working Capital is:

	Working Capital		(Q: Jun. 2017 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.104	+	0	+	0.012)	-	(0.337	+	0	+	0.749)
=	-0.97

	Working Capital		(Q: Sep. 2017 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.166	+	0	+	0.021)	-	(0.434	+	0	+	0.869)
=	-1.116

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2017) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Proto Script Pharmaceutical's Operating Margin % for the quarter that ended in Sep. 2017 is calculated as:

Operating Margin %	=	Operating Income (Q: Sep. 2017 )	/	Revenue (Q: Sep. 2017 )
	=	-0.085	/	0.252
	=	-33.73 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Proto Script Pharmaceutical Operating Income Related Terms

Thank you for viewing the detailed overview of Proto Script Pharmaceutical's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Proto Script Pharmaceutical (Proto Script Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Business Services » Proto Script Pharmaceutical Corp (OTCPK:PSCR) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

9830 6th Street, Suite 103, Rancho Cucamonga, CA, USA, 91730

Website

http://www.psphomecare.com

Proto Script Pharmaceutical Corp is primarily in the business of repair power wheelchairs and scooters, which are classified as durable medical equipment (DME) products and reimbursable by healthcare insurance providers. It has various contracts with state and governmental insurance providers, among others. These contracts provide the company with the right to sell and repair DME and its health care insurance contracts allow it the ability to service patients nationally. The group currently has its presence of repair facilities in Las Vegas, Nevada, Rancho-Cucamonga, and Anaheim, California.

Proto Script Pharmaceutical (Proto Script Pharmaceutical) Headlines

No Headlines